Abstract
The emergent need to treat COVID-19 patient must be tempered with safe use of drugs. The guideline set forth provides parameters for dosing and monitoring hydroxychloroquine in this population, reducing the occurrence of adverse effects and improving overall pharmacotherapy.
Highlights
The emergent need to treat COVID-19 patient must be tempered *Correspondence to Author: with safe use of drugs
Hydroxychloroquine is rapidly emerging as a first-line contender in the armamentarium against COVID19
At combined with observed QTc at time of peak absorption of medication into the bloodstream will aid in determine any subsequent dosage adjustments
Summary
The emergent need to treat COVID-19 patient must be tempered *Correspondence to Author: with safe use of drugs. Guidelines for Safe and Effective Use of Hydroxychloroquine in COVID-19 Patients. At combined with observed QTc at time of peak absorption of medication into the bloodstream will aid in determine any subsequent dosage adjustments. At time of peak hydroxychloroquine ingestion (average of 4 hours status post dose), an observed QTc these doses, viriological clearance and widening up to 25-35% baseline is expected.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.